OXGN Safety Go-Ahead in Zybrestat Trials
- OXiGENE, Inc. (NASDAQ:OXGN) reported interim results from a Phase II ovarian cancer study evaluating a combination of Zybrestat and bevacizumab. The two drugs passed a … Continue Reading
Read nowAuthor Archives: Editorial Staff
Rumor Mill Churns Out 5% Gain for One-Trick Pony Alexion
- Alexion Pharmaceuticals (NASDAQ:ALXN) continued to show top-line growth in its second quarter report issued last week. The company beat analyst expectations for the quarter and … Continue Reading
Read nowAfter Earnings, RMD is an Expensive Stock in Front of Major Risks
Short Ideas - ResMed (NYSE:RMD) reported revenues of $371.9 million and EPS of $0.53 for its fiscal fourth quarter (ended June), above Wall Street consensus estimates of $368 … Continue Reading
Read nowOMPI Down on Technicals; Buying Opportunity in Positive-Cash Flow Company
Long Ideas - After its Q2 earnings report was released last night, Obagi Medical Products (NASDAQ:OMPI) took a dive this morning, down 22.5% just after the bell. The … Continue Reading
Read nowGlaxo’s New Drugs Perform Well in Trials; Watch for Long-Term Gains
Long Ideas - The FDA has two new drugs in its queue this morning after GlaxoSmithKline (NYSE:GSK) submitted two new melanoma treatments, dabrafenib and trametinib, to the U.S. … Continue Reading
Read nowROSG Prices Public Offering, Feels the Sting
- Rosetta Genomics (NASDAQ:ROSG) tumbled after the company announced last night that it would be initiating a $27.5MM public offering. Shares are down 15% premarket and … Continue Reading
Read nowInvestors Usher MAKO Back to Square One; Q2 Report May Be Turnaround Point
Long Ideas - Shares of MAKO Surgical (NASDAQ:MAKO) are moving up today, trading higher by roughly 5% after yesterday’s earnings report. In the last four months, MAKO tumbled … Continue Reading
Read now